MedTrace Logo

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

NCT04067414 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-02-11

No results posted yet for this study

Summary

This is an open-label, multicenter, dose-escalation phase 1 study to determine the safety and efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma.

Conditions

Interventions

BIOLOGICAL

BZ019

Subjects will be enrolled in three dose-groups: Dose 1: 1×10\^6/kg CAR+ cells; Dose 2: 3×10\^6/kg CAR+ cells; Dose 3: 6×10\^6/kg CAR+ cells.

Sponsors & Collaborators

  • Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.

    collaborator UNKNOWN

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • Lugui Qiu, MD · Institute of Hematology & Blood Diseases Hospital, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-08
Primary Completion
2021-06-04
Completion
2021-06-04

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04067414 on ClinicalTrials.gov